company background image
HCWB

HCW Biologics NasdaqGM:HCWB Stock Report

Last Price

US$2.24

Market Cap

US$80.3m

7D

-8.2%

1Y

-39.0%

Updated

25 Sep, 2022

Data

Company Financials +
HCWB fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

HCWB Stock Overview

HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases.

HCW Biologics Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for HCW Biologics
Historical stock prices
Current Share PriceUS$2.24
52 Week HighUS$7.05
52 Week LowUS$1.76
Beta0
1 Month Change-13.85%
3 Month Change4.19%
1 Year Change-38.96%
3 Year Changen/a
5 Year Changen/a
Change since IPO-64.44%

Recent News & Updates

Aug 25
We Think HCW Biologics (NASDAQ:HCWB) Can Afford To Drive Business Growth

We Think HCW Biologics (NASDAQ:HCWB) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

HCWBUS BiotechsUS Market
7D-8.2%-5.0%-5.2%
1Y-39.0%-30.0%-23.0%

Return vs Industry: HCWB underperformed the US Biotechs industry which returned -30% over the past year.

Return vs Market: HCWB underperformed the US Market which returned -23% over the past year.

Price Volatility

Is HCWB's price volatile compared to industry and market?
HCWB volatility
HCWB Average Weekly Movement9.3%
Biotechs Industry Average Movement11.1%
Market Average Movement6.9%
10% most volatile stocks in US Market15.8%
10% least volatile stocks in US Market2.8%

Stable Share Price: HCWB is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: HCWB's weekly volatility has decreased from 15% to 9% over the past year.

About the Company

FoundedEmployeesCEOWebsite
201844Hing Wonghttps://www.hcwbiologics.com

HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company’s lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia.

HCW Biologics Inc. Fundamentals Summary

How do HCW Biologics's earnings and revenue compare to its market cap?
HCWB fundamental statistics
Market CapUS$80.27m
Earnings (TTM)-US$11.88m
Revenue (TTM)US$3.57m

22.5x

P/S Ratio

-6.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
HCWB income statement (TTM)
RevenueUS$3.57m
Cost of RevenueUS$1.62m
Gross ProfitUS$1.96m
Other ExpensesUS$13.83m
Earnings-US$11.88m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.33
Gross Margin54.77%
Net Profit Margin-332.51%
Debt/Equity Ratio0%

How did HCWB perform over the long term?

See historical performance and comparison